Bioneer’s Director of Research and Development, Christian Clausen (email), is leading a team of scientists to advance early drug discovery for immuno-oncology and neurodegenerative disease modeling.
In a fascinating interview with independent science publisher SelectScience, Clausen outlines how the disease modeling team is taking the next step, by working on a methodology that combines high-throughput and 3D imaging of Bioneer’s 3D cellular models.
Clausen tells SelectScience Deputy Editor Sarah Thomas: “In recent years, it has become more and more clear that moving these models and technologies into a combination of 3D and high-throughput setups would give a range of new ways to solve early drug discovery projects for our customers.”
He highlights how the ImageXpress Micro Confocal High-Content Imaging platform from Molecular Devices will play a vital role in this work, helping the team to establish assays for screening small molecules and checkpoint inhibitors for their effects on 3D immune-cancer spheroids, as well as assays to monitor neurite outgrowth in a human induced pluripotent stem (iPS) cell model.
Looking ahead, Clausen’s team will be using this approach to support partners in biotech and large pharma to qualify lead candidates earlier and, subsequently, improve R&D productivity in immuno-oncology and neurodegenerative disease drug discovery.
Read Clausen’s full interview on SelectScience here>>
Read more about Bioneer’s R&D program within Predictive 3D Cell Models here.